The Asian vaccine market is relatively small compared to its population, yet it is growing, and pharmaceutical manufacturers increasingly will look to boost sales from these emerging vaccine markets. The population of nearly 4 billion people throughout Asia accounts for more than half of the global population, yet currently it is Western markets which lead vaccine sales. This hasn't stopped companies from investing in Asian vaccine markets.
The graying of the population in Asia and the growth in some regions such as India and China are primary indicators of the potential for vaccine markets. This has encouraged market participants to increase spending in research and development and distribution facilities in Asian countries. This report examines the market for vaccines used in humans for various types of disease. It covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable; it does not cover emerging vaccines for diseases that are not currently vaccine-preventable.
As part of its coverage, this report includes:
Key issues in the global vaccine market today include product safety, refusal to immunize, supply shortages, the use of vaccines to prevent pandemics and address bioterrorism, and innovations in vaccine delivery systems. Vaccination has played an enormous role in the prevention of disease, having had the greatest impact on human health of any medical intervention. As a result, vaccine-preventable diseases and their resulting deaths are now rare in the developed world. However, developing nations have not benefited as much from the introduction of vaccines. Additionally, other issues such as vaccine safety, shortages and bioterrorism continue to weigh upon the industry.
The following companies are profiled in this report:
For the purpose of this report, secondary research into company reports, medical journals, trade publications and government reports was combined with primary research interviews of executives in the industry. In addition to this report, Kalorama has published research on the European vaccine industry and a look at what vaccines are in the pipeline in the future. Please see our website, www.kaloramainformation.com for more details on these studies.
All Kalorama reports advertise the single user price. Use is limited to one user. We also feature department and global pricing for reports that we be utilized by more than one user at your company. Please consult ask your sales representative or select the correct license on our website.
For Kalorama's take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information's Key Point Blog at http://kaloramakeypoint.blogspot.com/
It is estimated that at least two million children die each year from diseases that could have been prevented by already existing vaccines. More than 1.2 million of these deaths, 90% of which occur in the developing world, are a result of pneumococcal diseases, according to the WHO. Pneumococcal conjugate vaccines (PCV) are taking aim at these diseases and healthcare market research publisher Kalorama Information estimates in its new report, Asian Vaccine Markets, that PCV revenue in Asia grew 18.1% annually since 2006 to reach $442 million in 2010.
"Pneumococcus is a leading cause of serious illness worldwide, and is the most frequent cause of pneumonia, blood infections, sinusitis, and middle ear infections," said Bruce Carlson, publisher of Kalorama Information. "Although all age groups may be affected, the highest rate of pneumococcal disease occurs in young children and the elderly."
In early 2010, the United Nations unveiled an action plan designed to save the lives of 10 million women and children over the next five years. Part of the UN's Millennium Development Goals, the plan calls for increased coverage of three important pediatric vaccines: PCV, rotavirus vaccine, and Haemophilus influenzae type b (Hib) vaccine. It is supported in part by the Bill and Melinda Gates Foundation, which committed $1.5 billion in funding. The initiative is expected to support continued growth of these vaccines.
As noted in Kalorama's report, PCV products include Pfizer's pneumococcal 7-valent conjugate vaccine Prevnar, which is approved for use in children and targets the seven most prevalent serotypes of pneumococcal bacteria (diphtheria CRM197 protein containing 4,6B,9V,14,18C,19F, and 23F). These are among the most resistant to antibiotics and cause 80% of pneumococcal disease in infants, including bloodstream infections and meningitis. The vaccine is 97% protective against invasive pneumococcal disease caused by vaccine serotypes in fully vaccinated children.
"With the continued expansion of Pfizer's Prevnar line, as well as the proliferation of new products from local and foreign manufacturers and distributors, we expect pneumococcal vaccine revenues to continue their double digit annual growth through 2014," said Carlson.
Asian Vaccine Markets details and analyzes the Asian market for pediatric and adult vaccines and provides forecasts through 2014. Data covers India, China, Japan, Korea, Indonesia and Rest of Asia. A review of regulatory and IP issues, disease statistics and manufacturer strategies, as well as profiles of top participating companies are included.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook